159 related articles for article (PubMed ID: 35015151)
1. The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery.
Sato S; Shimizu T; Ishizuka M; Suda K; Shibuya N; Hachiya H; Iso Y; Takagi K; Aoki T; Kubota K
Surg Today; 2022 Aug; 52(8):1160-1169. PubMed ID: 35015151
[TBL] [Abstract][Full Text] [Related]
2. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
3. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
Kayar R; Bastug Y; Tokuc E; Topaktas R; Akyurek EA; Kayar K; Artuk I; Ozturk M
Int Urol Nephrol; 2024 Feb; 56(2):509-518. PubMed ID: 37773579
[TBL] [Abstract][Full Text] [Related]
4. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Fucà G; Guarini V; Antoniotti C; Morano F; Moretto R; Corallo S; Marmorino F; Lonardi S; Rimassa L; Sartore-Bianchi A; Borelli B; Tampellini M; Bustreo S; Claravezza M; Boccaccino A; Murialdo R; Zaniboni A; Tomasello G; Loupakis F; Adamo V; Tonini G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F
Br J Cancer; 2020 Aug; 123(3):403-409. PubMed ID: 32424148
[TBL] [Abstract][Full Text] [Related]
5. A decreased preoperative platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value are associated with the poorer survival of patients with a stent inserted as a bridge to curative surgery for obstructive colorectal cancer.
Sato R; Oikawa M; Kakita T; Okada T; Abe T; Tsuchiya H; Akazawa N; Ohira T; Harada Y; Okano H; Ito K; Tsuchiya T
Surg Today; 2023 Apr; 53(4):409-419. PubMed ID: 35987967
[TBL] [Abstract][Full Text] [Related]
6. Effect of preoperative pan-immune-inflammation value on clinical and oncologic outcomes after colorectal cancer surgery: a retrospective study.
Seo YJ; Kim KE; Jeong WK; Baek SK; Bae SU
Ann Surg Treat Res; 2024 Mar; 106(3):169-177. PubMed ID: 38435496
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy.
Pérez-Martelo M; González-García A; Vidal-Ínsua Y; Blanco-Freire C; Brozos-Vázquez EM; Abdulkader-Nallib I; Álvarez-Fernández J; Lázare-Iglesias H; García-Martínez C; Betancor YZ; Sánchez-Ares M; Tubío JMC; Vázquez-Rivera F; Candamio-Folgar S; López-López R; Ruiz-Bañobre J
Sci Rep; 2022 Apr; 12(1):6893. PubMed ID: 35477740
[TBL] [Abstract][Full Text] [Related]
9. Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer.
Zhao H; Chen X; Zhang W; Cheng D; Lu Y; Wang C; Li J; You L; Yu J; Guo W; Li Y; Huang Y
Front Surg; 2022; 9():996844. PubMed ID: 36034356
[TBL] [Abstract][Full Text] [Related]
10. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
[TBL] [Abstract][Full Text] [Related]
11. Pan‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma.
Su Z; Tang J; He Y; Zeng WH; Yu Q; Cao XL; Zou GR
Oncol Lett; 2024 Jun; 27(6):252. PubMed ID: 38646495
[TBL] [Abstract][Full Text] [Related]
12. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
[No Abstract] [Full Text] [Related]
14. The prognostic importance of the pan-immune-inflammation value in patients with septic shock.
Turan YB
BMC Infect Dis; 2024 Jan; 24(1):69. PubMed ID: 38200436
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte-to-C-Reactive Protein Ratio Is the Most Sensitive Inflammation-Based Prognostic Score in Patients With Unresectable Metastatic Colorectal Cancer.
Nakamura Y; Shida D; Boku N; Yoshida T; Tanabe T; Takamizawa Y; Takashima A; Kanemitsu Y
Dis Colon Rectum; 2021 Nov; 64(11):1331-1341. PubMed ID: 34623347
[TBL] [Abstract][Full Text] [Related]
16. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
17. [Impact of neutrophil-to-lymphocyte ratio on the prognosis of patients with locally advanced colorectal cancer].
Jiang H; Wang H; Li A; Tang E; Chen Y; Wang A; Deng X; Lin M
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):550-554. PubMed ID: 28534334
[TBL] [Abstract][Full Text] [Related]
18. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
19. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer.
Toyokawa T; Muguruma K; Yoshii M; Tamura T; Sakurai K; Kubo N; Tanaka H; Lee S; Yashiro M; Ohira M
BMC Cancer; 2020 Jun; 20(1):517. PubMed ID: 32493247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
